Endometrial polypoid adenomyoma outcomes and fertility-sparing treatments efficacy for atypical type: A systematic review and network meta-analysis

Table 2 Rankings of interventions based on their ability to inhibit recurrence as indicated by surface under the cumulative ranking curve analysis

Treatment	SUCRA (%)	PrBest (%)	Mean rank
TCRP	45.3	2	7
TCRP + HDP	60.3	0	5.4
TCRP + MPA (10 mg/day)	65.3	0.2	4.8
TCRP + COC	47.4	4.8	6.8
TCRP + LNG-IUS	47.6	4.6	6.8
TCRP + GnRH-a	55.3	2.1	5.9
TCRP + PT	50.1	0.6	6.5
TCRE	53.9	22.8	6.1
TCRE + PT	58.2	17.1	5.6
PWH + HDP	43.2	17	7.3
PWH + HDP + MT	59.3	16.2	5.5
PWH	30.4	12.6	8.7

SUCRA: Surface under the cumulative ranking curve; PrBest: Probability of being the best; TCRP: Transcervical resection of polyps; LNG-IUS: Levonorgestrel-releasing intrauterine system; COC: Combined oral contraceptive; PT: Progesterone therapy; MPA: Medroxyprogesterone acetate; TCRE: Transcervical resection of endometrium; PWH: Polyp resection without hysteroscopy; HDP: High-dose progestin; MT: Hormone maintenance therapy; GnRH-a: Gonadotrophin-releasing hormone agonist.